This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Networking for the Life Sciences

Networking for the Life Sciences

Upcoming networking and mini-events

Networking opportunities

Networking Clubs

First Thursday of the month – Innovators
Second Thursday of the month – Leaders
Third Thursday of the month – Investments

Therapeutic Spotlight: Diabetes

Join in the Diabetes networking on Thursday, September 30 at 17:00 CEST.

Diabetes is an extremely common disease, affecting a wide range of people globally. Those diagnosed can experience additional significant health problems, affecting the quality of life, mortality rate, and diabetes-related healthcare cost. Although many treatments exist for diabetes management, there are opportunities to study the disease and take further prevention measures, and for researchers to improve the lifestyles of millions who struggle every day. This month, take the opportunity to unlock the potential of additional research in diabetes discovery, management and prevention.

Lev Goldin, Director, Business Development & Licensing - Cardiovascular, Metabolism, Endocrinology & Fertility & Commercial, Merck KGAa, will be on hand to talk about Merck’s activity in the diabetes field.

Interview Spotlights

Bringing you timely content and views from other members on a regular basis.

Please reach out to us, if you would like to be featured: 

Sustainable?? We take that to mean a number of important steps – green chemistry, whenever possible, being only one.

What does sustainability mean for Raybow and the team? 

We are now implementing our sustainability standards with our key suppliers to make sure that environmentally friendly processes are promoted and implemented as widely as possible.  

AN INTERVIEW WITH: Peter Halkjaer-Knudsen, EVP, Raybow Pharma

What inspires you to innovate?

Besides knowing EBD is making a difference by inspiring attendees and delivering a sustainable event, it can be actually quite satisfying to develop and implement creative content and purposeful initiatives to support our sustainability efforts. While the bulk of my role is planning and strategy around logistics, brainstorming and implementing original ideas always feels a little more personal.

AN INTERVIEW WITH: Michelle Murawski Senior Manager, Operations, EBD Group

Do you have any insights or top tips for others driving CSR/sustainability?

I think keeping everyone informed and engaged is the key to driving CSR and sustainability in the company. The CSR team were lucky to have a continual dialog with Kymab’s senior management, many of whom were committed to and passionate about sustainability, and this has helped to keep CSR high on the agenda. Company updates and the ability to share our targets and progress have also meant more of our colleagues are aware of what CSR means, and the positive impact we can and are making in the local and wider community.

AN INTERVIEW WITH: Dr. Natalie Rynkiewicz Research Scientist and CSR chair, Kymab Ltd

Join monthly mini-events on these topics


Watch these sessions and more on CONNECTOR

Venture Capital Has Advanced Innovation in China Life Science; It Needs to Do More

At the recent ChinaBio® Partnering Forum, a group of China VCs discussed their very vibrant field: $30 billion in VC investments last year, double the year before. More young companies need support and more capital is available for them. With all the activity, exits are taking place sooner, often before companies have launched a product. But the question remains: how innovative are these companies? Greg Scott, Chairman of ChinaBio®, led the discussion that included representatives of four China VC firms.


Greg B. Scott – Founder and Chairman ChinaBio® Group


Michael Keyoung, MD, PhD – Head of North America C-Bridge Capital

Yuwen Liu – Founding Partner BOHE Angel Fund, Bio2

Hongbo Lu, PhD – Partner Vivo Capital

Victor E. Tong – Partner Decheng Capital

Australian Regenerative Medicine Institute (ARMI) and CCRM Australia Interview


Susanna Ling – Business & Content Development Director EBD Group


Silvio Tiziani – Director, External Strategy and Planning Australian Regenerative Medicine Institute, CEO, CCRM Australia

Therapeutic: Patient-centered drug development in an age of cell and gene therapies

This session will focus on how the role of patients has evolved and is evolving in an era of gene and cell therapies. These new therapies present unique opportunities not only for patient involvement in the development process but pose new challenges, of all stakeholders, around the need for long-term follow up of outcomes from gene therapy. With hundreds of gene and cell therapies in the pipeline, and some now available to patients across global markets, how will we create more uniform approaches for engaging communities and sharing data and information? 

Craig Martin – CEO Global Genes

Rodolphe Clerval – CEO Horama
Sheila Mikhail – Co-founder and CEO Asklepios BioPharmaceutical (AskBio)
David Solomon – CEO Pharnext

Learning: Pandemic therapeutics: treating COVID-19 and beyond

While vaccines have taken the limelight, the biotech industry has been working just as hard to develop therapeutic treatments for COVID-19. From innovative new treatments to repurposing well-know drugs, identifying, testing, and manufacturing safe and effective treatments still face the same high bar for approval as before the pandemic, only with the added urgency of immediate need. Hear from some of the companies at the center of this effort about their individual initiatives as well as the broader collaborations established to address the current pandemic and thinking ahead to the next.

Alaric DeArment – Reporter Scrip

Cameron Durrant – Chairman and CEO, Humanigen
Leah Lipsich – VP, Strategic Program Direction, Regeneron
Holger Zimmermann – CEO, AiCuris

Learning: Answering the need: responsive CDMO partnerships

The pandemic has pressurized development, regulatory, manufacturing, and distribution timelines like never before and the biotech industry has responded rapidly to the urgent global needs for vaccines as well as other biopharmaceuticals. In the middle of this pressure-system are the people and companies that have come together to provide the needed solutions to the development and production crunch points. This collaboration close up will take a deep dive into the partnership between Rentschler Biopharma and BioNTech and examine what it took to make this collaboration successful. 

Lucie EllisView Profile – Executive Editor, In Vivo, Informa Pharma Intelligence

Oliver Hennig – Senior VP, Operations, BioNTech
Federico Pollano – Senior VP, Global Business Development, Rentschler Biopharma SE

Leading: Impact of COVID-19: Life sciences

What COVID-19 has brought upon the world is a triple inflection of change. Amazing technological advances, regulatory and reimbursement approval, and the profound social imperative for use all come together to make health tech no longer an option, but an imperative